The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,774.50
Bid: 1,774.00
Ask: 1,774.50
Change: -3.50 (-0.20%)
Spread: 0.50 (0.028%)
Open: 1,780.00
High: 1,793.50
Low: 1,766.50
Prev. Close: 1,778.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Risk-Off Mood As Weak UK Services Adds To Worry

Wed, 05th Dec 2018 12:12

LONDON (Alliance News) - London stocks slid on Wednesday as risk-off sentiment replaced the more upbeat mood at start of the week, with markets in the US and Asia slumping overnight amid global trade and economic growth concerns.Meanwhile, buyers of the pound weren't fazed by disappointing data on the UK's crucial services industry, which suggested that Brexit anxiety has weighed on business activity and sentiment in November."Given the scale of the sell-off in the US, many would have expected a very bleak day for European markets. But with the US out of the picture today, things are quieter. Besides, the FTSE and others had not joined in the big rally last week following Jerome Powell's speech, held back by a stronger pound and euro as the dollar dropped," said IG chief market analyst Chris Beauchamp.He added: "However, indices on this side of the Atlantic are now back to the lows of November - while this might hold, the outlook does not look particularly encouraging."The FTSE 100 index at midday was down 81.57 points, or 1.2%, at 6,941.19. The FTSE 250, however, was up 0.1%, or 17.88 points, at 18,347.52. The AIM All-Share was 0.9% lower at 913.63.The Cboe UK 100 was down 1.3% at 11,778.28, while the Cboe UK 250 was up 0.2% at 16,415.02. The Cboe UK Small Companies was down 0.6% at 11,333.37.In mainland Europe at midday, the CAC 40 index in Paris and the DAX 30 in Frankfurt were down 0.9% and 0.8%, respectively. Markets in the US are closed on Wednesday for the funeral of former US President George HW Bush.The pound was broadly unchanged at USD1.2742 compared to USD1.2732 late Tuesday despite the weak print on the UK's dominant services sector.The closely watched IHS Markit/CIPS UK services Purchasing Managers' Index showed a reading of 50.4 in November, falling dangerously close to the no-change mark of 50 after October's level of 52.2. The PMI figure had been expected to be unchanged from October. November saw the worst performance since July 2016, when business sagged following the result of the referendum on Britain's membership of the EU. Excluding July 2016, it was also the worst performance since February 2013.The survey suggests that Brexit anxiety has weighed on business activity and sentiment with companies more risk averse when making spending and investment plans following reports that Britain could crash out of the EU with no deal."The bottom line is that fourth quarter growth is likely to be noticeably lower than in the third, and as we noted on Monday, we have our doubts that this will be heavily offset by pre-Brexit inventory building. While recent Bank of England commentary has made it clear that policymakers would like to resume tightening fairly soon given the stronger wage growth backdrop, we don't expect a rate hike before May 2019 - with a clear risk that this could be pushed back later into 2019," commented James Smith, developed markets economist at ING.Meanwhile, Markit's composite PMI for the eurozone fell to 52.7 in November from October's 53.1.In other data from the currency bloc, eurozone retail sales grew in October after decreasing in the previous month. Retail sales grew 0.3% from September, when they fell 0.5%, after the stagnation reported earlier was revised. Economists had forecast a 0.2% increase for October. Among the fallers in the FTSE 100 on Wednesday was rental equipment firm Ashtead, down 4.4% as investors fretted over a possible slowdown in US economic growth. Of Ashtead's GBP3.71 billion in revenue generated in the financial year ended April 30, US unit Sunbelt contributed a whopping GBP3.10 billion, or 84%."The firm, which was (and arguably remains) such a good way to play US economic growth, is the first port of call when worries about said growth are dominating minds. But with Monday's ISM manufacturing PMI near the highs for a decade, perhaps investors are overly concerned," commented IG's Beauchamp. Hargreaves Lansdown was down 4.0% after Morgan Stanley late Tuesday downgraded the fund supermarket to Underweight from Equal Weight. GlaxoSmithKline also was knocked by a broker's opinion, falling 3.3% after Barclays cut the pharma giant to Equal Weight from Overweight.Meanwhile, fellow drugmaker Shire was up 2.7% after after Takeda Pharmaceutical shareholders approved the acquisition of the Irish drugmaker.The acquisition remains subject to approval by Shire shareholders at a meeting expected to be held later Wednesday, and it is expected that completion of the acquisition will take place on January 8.In the FTSE 250, Stagecoach was among the best performers as it gained 11% on a set of better-than-expected interim results, despite swinging to a loss. Adjusted pretax profit fell to GBP87.0 million in the half-year to October 27 from GBP96.7 million a year before, as the company swung to a statutory pretax loss of GBP22.6 million from a GBP96.7 million profit reported for the same period a year earlier. Operating profit for UK Rail was highlighted as being ahead of forecasts, despite profit for the unit falling 47% to GBP11.5 million from GBP21.7 million a year ago. The company said the fall reflected the expiry of the South West Trains franchise."The group is focused on making further progress in the second half of the year and we have increased our expectation of full-year adjusted earnings per share to reflect the above-forecast rail earnings in the first half of the year," said Chief Executive Martin Griffiths.Thomas Cook was the top gainer in the FTSE 250, shares jumping 36% as the travel agent moves on from a miserable time last week. Thomas Cook issued a profit warning on Tuesday last week just days before the release of its annual results as it also suspended the payment of a final dividend. The company also looks set to be ejected from the FTSE 250 in the quarterly index review, the results of which will be released after the market close on Wednesday. Among other possible index changes, Royal Mail is facing demotion from the FTSE 100 to be replaced by insurer Hiscox. Aston Martin and Funding Circle are among the stocks up for membership in the FTSE 250.Despite Thomas Cook's significant gain on Wednesday, the stock remains 74% lower since the start of 2018.

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.